

# Anti-TNFSF11 (Denosumab), Human IgG2 Antibody

rev 01/21

---

**CATALOG NO.:** A2150-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a fully human IgG2 monoclonal antibody that specifically targets receptor activator of nuclear factor kappa-B ligand (RANKL), a protein that plays a key role in the formation, function, and survival of osteoclasts. RANKL belongs to the TNF superfamily of ligands. Interaction with the receptor (RANK) expressed on pre-osteoclast and mature osteoclast cells results in the activation, migration, differentiation, and fusion of hematopoietic cells of osteoclast lineage, and promotes bone resorption. By preventing the RANKL-RANK interaction, the antibody inhibits bone resorption and increases bone mass density and strength, thus decreasing the risk of hip, vertebral, and non-vertebral fractures. The original monoclonal antibody received approval from the FDA for the treatment of osteoporosis in postmenopausal women, and to treat patients with bone metastases

**ALTERNATE NAMES:** CD254, ODF, OPGL, sOdf, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** Lot specific

**HOST/ISOTYPE:** Recombinant / IgG2, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human TNFSF11

**CAS NUMBER:** 615258-40-7

**MOLECULAR WEIGHT:** 144.7 kDa

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C. Avoid freeze/thaw cycles

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

Anti-VEGF (Bevacizumab), Humanized Antibody (A1045)

Anti-HER2 Humanized Antibody (A1046)

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)

Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)

**FOR RESEARCH USE ONLY! Not to be used on humans.**